Regulations.gov document
Determination That ARISTOSPAN (Triamcinolone Hexacetonide) Injectable Suspension, 20…
Notice · FDA-2022-P-1104 · posted Feb 13, 2023
Key facts
| Document ID | FDA-2022-P-1104-0005 |
|---|---|
| Title | Determination That ARISTOSPAN (Triamcinolone Hexacetonide) Injectable Suspension, 20 Milligrams/ Milliliter and 5 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2022-P-1104 |
| Posted | Feb 13, 2023 |
| Federal Register citation | 88 FR 9298 |
| FR document number | 2023-02984 |
| Comment period opens | Feb 13, 2023 |
| Effective date | Feb 13, 2023 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: